Mendelian Randomization Study of SGLT-2 Inhibitors and Constipation

A two-sample Mendelian randomization study investigates the causal effect of SGLT-2 inhibition on constipation risk, analyzing 452 circulating metabolites for mediation. The dataset contains genetic association results, including odds ratios and confidence intervals, from summary-level genome-wide association studies. It was authored by Qiuhui Liu and published in 2026.

Use Cases

• Analyze the association between genetically proxied SGLT-2 inhibition and constipation risk using odds ratios and confidence intervals from the primary analysis.
• Investigate the mediating role of the metabolite DSGEGDFXAEGGGVR in the protective effect, quantifying its 22.76% mediation proportion.
• Perform sensitivity analyses on the causal relationship using the inverse-variance weighted method and supplementary MR techniques.
• Examine genetic instrument data derived from SLC5A2 gene expression and glycated hemoglobin (HbA1c) levels for SGLT-2 inhibition.

Strengths

• Analysis is based on summary-level data from large-scale genome-wide association studies (GWAS).
• Examines a panel of 452 circulating metabolites for potential mediation effects.
• Results include specific statistical measures like an odds ratio of 0.31 and a mediation proportion of 22.76%.
• Dataset is published under a permissive CC BY 4.0 license.

Limitations

• The dataset is small in file size (100.7 KB), indicating it contains summary results rather than raw individual-level genetic data.
• Specific row and column counts are not provided, limiting assessment of the underlying data's granularity.
• Causal inferences are based on genetic proxies and summary statistics, which may not capture all clinical complexities.

Provenance

Source

figshare, authored by Qiuhui Liu.

Collection Method

Two-sample Mendelian randomization using genetic instruments from GWAS summary statistics.

Freshness

Last updated in March 2026.